Little is known about substitutions that mediate resistance of hepatitis C virus (HCV) to direct-acting antivirals (DAAs), due to the small number of patients with treatment failure in approval studies. It is important to identify resistance patterns to select effective salvage treatments. METHODS: We performed a comprehensive analysis for resistance-associated substitutions (RASs) in HCV genes (nonstructural protein [NS]3, NS5A, NS5B) targeted by DAAs. We compared NS3, NS5A, and NS5B sequences from 626 patients in Europe with DAA failure with sequences from 2322 DAA-naïve patients, infected with HCV genotypes 1 to 4. We considered RASs to be relevant if they were associated with DAA failure in patients or conferred a greater than twofold change in susceptibility compared with a reference strain in in vitro replicon assays. Data were collected on pretreatment status, DAA regimen, the treatment initiation date and duration, and virologic response. Patients who received at least 4 weeks of antiviral treatment were included in the analysis. RESULTS: RASs in NS3 associated with simeprevir or paritaprevir failure include R155K and D168E/V. In addition, several RASs were specifically associated with failure of simeprevir (Q80K/R in patients with genotype 1a or 4) or paritaprevir (Y56H in combination with D168V in patients with genotype 1b). Y93H in NS5A was the RAS most frequently associated with failure of daclatasvir, ledipasvir, or ombitasvir in patients with genotype 1b infection, and L31M was associated with failure of daclatasvir or ledipasvir, but not ombitasvir. RASs in NS5A were heterogeneous among patients with HCV genotype 1a or genotype 4 infections. In patients with HCV genotype 3, Y93H was associated with resistance to daclatasvir, but no RASs were associated with ledipasvir failure, pointing to a limited efficacy of ledipasvir in patients with genotype 3. Among patients failed by sofosbuvir-containing regimens, L159F was enriched in patients with genotype 1b (together with C316N) or genotype 3 infection, whereas the RAS S282T was rarely observed. CONCLUSIONS: We compared RASs in NS3, NS5A, and NS5B among patients failed by DAA therapy. Theses varied with the HCV genotype and subtype, and the different drug classes. These findings might be used to select salvage therapies.
BACKGROUND & AIMS:
Little is known about substitutions that mediate resistance of hepatitis C virus (HCV) to direct-acting antivirals (DAAs), due to the small number of patients with treatment failure in approval studies. It is important to identify resistance patterns to select effective salvage treatments. METHODS: We performed a comprehensive analysis for resistance-associated substitutions (RASs) in HCV genes (nonstructural protein [NS] 3, NS5A, NS5B) targeted by DAAs. We compared NS3, NS5A, and NS5B sequences from 626 patients in Europe with DAA failure with sequences from 2322 DAA-naïve patients, infected with HCV genotypes 1 to 4. We considered RASs to be relevant if they were associated with DAA failure in patients or conferred a greater than twofold change in susceptibility compared with a reference strain in in vitro replicon assays. Data were collected on pretreatment status, DAA regimen, the treatment initiation date and duration, and virologic response. Patients who received at least 4 weeks of antiviral treatment were included in the analysis. RESULTS: RASs in NS3 associated with simeprevir or paritaprevir failure include R155K and D168E/V. In addition, several RASs were specifically associated with failure of simeprevir (Q80K/R in patients with genotype 1a or 4) or paritaprevir (Y56H in combination with D168V in patients with genotype 1b). Y93H in NS5A was the RAS most frequently associated with failure of daclatasvir, ledipasvir, or ombitasvir in patients with genotype 1b infection, and L31M was associated with failure of daclatasvir or ledipasvir, but not ombitasvir. RASs in NS5A were heterogeneous among patients with HCV genotype 1a or genotype 4 infections. In patients with HCV genotype 3, Y93H was associated with resistance to daclatasvir, but no RASs were associated with ledipasvir failure, pointing to a limited efficacy of ledipasvir in patients with genotype 3. Among patients failed by sofosbuvir-containing regimens, L159F was enriched in patients with genotype 1b (together with C316N) or genotype 3 infection, whereas the RAS S282T was rarely observed. CONCLUSIONS: We compared RASs in NS3, NS5A, and NS5B among patients failed by DAA therapy. Theses varied with the HCV genotype and subtype, and the different drug classes. These findings might be used to select salvage therapies.
Keywords: HCV; RASs; DAA; Virologic Treatment Failure. S everal combination regimens based on direct-acting antivirals (DAAs) that target proteins with crucial functions in the hepatitis C virus (HCV) replication cycle are approved for the treatment of chronic hepatitis C. 1 Although rates of sustained virologic response (SVR) are high, because of the large number of infected patients, a substantial number will require a rescue treatment.
2 Virologic failure to DAA-based therapies is associated with the selection of resistant viral isolates and retreatment with the same regimen has limited efficacy. 1, 3, 4 Therefore, the knowledge of patterns of resistance-associated substitutions (RASs) selected after treatment failure to the different DAAbased regimens may be useful for selection of individual, effective salvage treatment options and resistance testing is recommended by international guidelines in this setting.
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Due to the high antiviral efficacy, limited data from the approval studies are available on RASs selected in patients with treatment failure. The major sofosbuvir (SOF) RAS S282T was observed in a few patients only. [6] [7] [8] In phase 2/3 studies for simeprevir (SMV) plus sofosbuvir, only 34 patients had a virologic treatment failure. [9] [10] [11] For regimens with sofosbuvir and the nonstructural protein (NS)5A inhibitors ledipasvir (LDV) and daclatasvir (DCV), 51 and 36 treatment failures were detected in the phase 2/3 studies, respectively. 7, [12] [13] [14] [15] Finally, for the large phase 3 development program of the combination of paritaprevir/ritonavir, ombitasvir, and dasabuvir (3D regimen) overall 40 patients with virologic failure were reported. [16] [17] [18] Because of the lack of the availability of a commercial assay and the limited number of patients with virologic failure at each study site, a centralized HCV resistance analysis was performed for the European resistance study group. Based on the data from a very large number of DAA-naïve patients (n ¼ 2323) and patients with a failure to sofosbuvir/pegylated interferon/ribavirin (SOF/RBV þ PEG IFN) (n ¼ 63), sofosbuvir/ribavirin (SOF/RBV) (n ¼ 132), simeprevir/sofosbuvir (n ¼ 55), ledipasvir/sofosbuvir (n ¼ 232), daclatasvir/sofosbuvir (n ¼ 89), and 3D/2 DAA regimen (paritaprevirþ ombitasvir) (2D) (n ¼ 55), for the first time a comprehensive and comparative analysis of HCV RASs patterns was possible in the present study.
Methods

Patients
In this noninterventional epidemiological study, serum of 4240 patients with a chronic hepatitis C infection with genotypes 1 to 6 was sent from study sites of different European countries to our laboratory for routine diagnostic HCV resistance testing. Information of the pretreatment status was provided on the resistance analysis submission form. We excluded individuals with insufficient data regarding the treatment status and patients who received investigational DAAs within a clinical study. Moreover, special geno-and subtypes (GT1c, 1e, 1l, GT2k/1b chimeras that were published separatly, 19 GT5 and 6) and boceprevir/telaprevir-treated patients were not included, leaving 2322 DAA-naïve and 626 DAA-experienced patients for all further analyses (Supplementary Figure 1) . After completion of resistance testing, data were collected from individuals with a DAA treatment failure in a retrospective manner, including the documentation of limited parameters, such as cirrhosis, the pretreatment status, the administered DAA regimen, the treatment initiation date and duration, as well as the virologic response. Patients who received at least 4 weeks of antiviral treatment were included. Investigations were performed according to the Declaration of Helsinki, and approval of the usage of patient blood samples and retrospective collection of data for research purpose was obtained from the local ethics committee (Ethikkommission der J. W. Goethe-Universität Frankfurt).
NS3, NS5A, and NS5B Amplification and Sequencing
The HCV RNA extraction and cDNA synthesis were performed as described previously. 20 The NS3, NS5A, and NS5B DAA target regions were amplified by nested polymerase chain reactions (PCRs) using 1/10 of cDNA and outer PCR product, respectively, and the Fast Cycling PCR Kit (Qiagen, Hilden, Germany). All PCR amplifications started with an initial denaturation step for 5 minutes at 95 C. Each cycle consisted of a denaturation step at 96 C for 5 seconds, and an annealing at the temperature described in the supplementary information for 5 seconds followed by an extension step at 68 C for 1 minute. Finally, PCR reactions were completed by an extension step at 72 C for 1 minute. The number of PCR cycles and the primer sequences are listed in the supplementary information. Resulting PCR products were gel-purified using the QIAquick Gel Extraction Kit (Qiagen). Population sequencing was performed with primers as denoted in the supplementary information and the Big Dye Terminator v3.1 Cycle Sequencing Kit on an ABI Prism 3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA).
Analysis of RASs
All sequences were proofread and aligned using BioEdit version 7.2.5 (T. Hall, Ibis Therapeutics, Carlsbad, CA). We considered RASs as relevant if they were described to be associated with treatment failure in vivo and/or if they conferred a greater than twofold changed drug susceptibility in comparison with a wild-type reference strain in in vitro replicon assays that were mainly conducted by the industry and published in several studies. 1, 3 All analyzed RASs are listed in the supplementary information. Fold change resistance levels are an indication, but they depend on the type of the assay used and are not directly comparable between different studies. As described in previous reports, 20, 21 also minority RASs were regarded as relevant that were detectable as mixed peaks in the electropherogram, whereby a sensitivity of approximately 15% to 20% can be assumed for population sequencing. 20 A reevaluation of HCV geno-and subtypes was performed on the
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basis of the obtained nucleotide sequences and sequences were designated as wild-type when no RASs were detected.
We compared RASs before and after a DAA-based treatment, and when combined RASs were detected in one viral variant they were counted as single RAS. To calculate the frequency of RASs, the number of each RAS was divided by the overall number of target gene sequences. As in the vast majority of cases, matched samples of the same patient before and after a DAA treatment failure were not available, we performed overall comparisons of DAA-naïve versus DAA-experienced patients for each genotype and treatment regimen.
Results
Virological Characteristics of Patients With a DAA Failure
The vast majority of patients had a relapse (84%), whereas a nonresponse/breakthrough was detected in 6% of individuals only (the remaining 10% of patients discontinued treatment or the type of failure was not specified). Interestingly, patients with a nonresponse/ breakthrough exhibited higher prevalences of DAA-specific RASs compared with individuals with a relapse (86% vs 66%, respectively). Moreover, we detected in 1.7% of patients another genotype after DAA failure compared with the one determined before treatment initiation by commercial assays (data not shown).
NS5B RASs After Sofosbuvir/Ribavirin AE Pegylated Interferon
We investigated the prevalence of NS5B nucleotide inhibitor RASs in patients after treatment with sofosbuvir/ribavirin with or without pegylated interferon in comparison with their frequencies before treatment initiation. Patients with GT1a (n ¼ 35) or GT2 (n ¼ 26) did not develop NS5B RASs after treatment failure (data not shown). Interestingly, in individuals with GT1b, L159F was selected in combination with C316N (32% and 55%, respectively) after treatment failure ( Figure 1A ). In GT3, slight increases of L159F (5%) and V321A (2%) were observed, whereas both variants were not found in DAA-naïve patients ( Figure 1B) . The median sampling time after end of treatment (EOT) was 5 to 6 months for both regimens. C316N is frequently associated with L159F in GT1b and was also observed after failure to other sofosbuvir-containing regimens (data not shown). However, L159F and V321A are not associated with a reduced sofosbuvir susceptibility. The only known variant conferring sofosbuvir resistance in vitro is S282T, which was not detected in any of these patients.
NS3 RASs After Simeprevir/Sofosbuvir Treatment Failure
After failure to a simeprevir/sofosbuvir treatment, characteristic RASs developed within NS3. Patients with GT1a showed an increase of Q80K (56%) which confers only low-level resistance to simeprevir in vitro but is associated with a reduced treatment response in vivo. Moreover, medium-to high-level resistant R155 and D168 variants were frequently detected (44% and 25%, respectively); R155K and D168E were most prominent ( Figure 2A ). In GT1b, the resistance profile was dominated solely by D168 variants (41%) and D168V was characteristic ( Figure 2B ). Patients infected with GT4 who did not achieve an SVR were rare (n ¼ 4) and here Q80R and D168E Figure 1 . NS5B nucleotide inhibitor RASs following sofosbuvir/ribavirin±pegylated-interferon treatment in comparison with DAA-naïve patients. Frequencies of RASs in patients infected with GT1b (A) and in individuals with GT3 (B). The number of investigated patients is displayed at the top of the figure as well as the median time of the RAS analysis in relation to the EOT with the range stated in parentheses. Typical patterns of RASs are highlighted by red frames and major increasing RASs are indicated in red letters. At the bottom, resistance levels are specified according to Svarovskaia et al, 52 and the number of sequences analyzed is indicated.
were selected ( Figure 2C ). The median sampling time was between 4 and 7 months after EOT for all GT.
NS5A RASs in Patients With Daclatasvir/ Sofosbuvir Versus Ledipasvir/Sofosbuvir Failure
To investigate differences in the development of RASs, we compared the frequencies of NS5A RASs after failure to daclatasvir or ledipasvir in combination with sofosbuvir in patients with GT1-4. In GT1a-infected patients, high-level resistant RASs appeared at position Q30 after failure to daclatasvir/sofosbuvir and ledipasvir/sofosbuvir (71% and 52%, respectively) and Q30H/R variants were most common. Moreover, L31 variants were detectable to a lesser extent (24% and 14%, respectively). However, differences were observed for both regimens, as moderate frequencies of Y93 variants (30%) were characteristic for a ledipasvir/ sofosbuvir failure and were infrequent after daclatasvir/ sofosbuvir ( Figure 3A) .
The resistance profile in GT1b was comparable for both regimens and L31 and Y93 variants increased (58% and 83% after daclatasvir/sofosbuvir; 50% and 80% after ledipasvir/sofosbuvir), with L31M and Y93H being most prevalent ( Figure 3B ). In GT3, high-level resistant Y93H was Figure 2 . NS3 RASs detected in patients after simeprevir/sofosbuvir treatment in GT1a (A), GT1b (B), and GT4 (C) in comparison with their frequencies in DAA-naïve patients. At the top of the figure the number of patients is included, the median time of the RAS analysis in relation to the end to treatment with the range stated in parentheses is indicated. Patterns of RASs are highlighted using red frames and major increasing RASs are designated in red letters. The resistance levels according to References 29, 30, and 53 , as well as the number of sequences investigated are listed at the bottom. also characteristic after daclatasvir/sofosbuvir administration (66%), whereas it was completely lacking in ledipasvir/ sofosbuvir-treated patients ( Figure 3C ). In GT4, infection mainly occurred with subtypes 4a and 4d and only a limited number of patients could be investigated after daclatasvir/ sofosbuvir failure (n ¼ 3). Interestingly, low-level resistant L30R was already detectable at relatively high frequencies in DAA-naïve patients, especially in those with subtype 4d. After DAA failure, RASs at position L28 were prominent (66% daclatasvir/sofosbuvir and 39% ledipasvir/ sofosbuvir), which mainly was caused by an increase of lowlevel resistant L28M. Moreover, Y93 variants appeared (33% daclatasvir/sofosbuvir and 39% ledipasvir/sofosbuvir) with Y93C/H variants mainly detected ( Figure 3D ).
Within NS5B, S282T was found after daclatasvir/sofosbuvir or ledipasvir/sofosbuvir failure in a few patients only (for daclatasvir/sofosbuvir and GT3 n ¼ 2 [5%], for daclatasvir/sofosbuvir and GT4 n ¼ 1
The median sampling time point was 3 to 6 months after EOT for all genotypes and regimens.
RASs in 3D/2D Failures
Components of the 3D regimen are the protease inhibitor (PI) paritaprevir/ritonavir, the NS5A inhibitor ombitasvir, and the non-nucleoside NS5B inhibitor dasabuvir, which is approved as triple combination (3D) for the treatment of GT1 and as dual therapy (2D, consisting of paritaprevir/ritonavir and ombitasvir) for GT4.
Within GT1a NS3, increasing RASs after 3D failure were located at position R155 and D168 (22% and 44%) and here characteristic RASs were medium-level resistant R155K and D168V. In GT1b, high-level resistant D168V was selected frequently in combination with Y56H. Regarding NS5A, in GT1a the frequencies of the most common RASs were 30% and 60% at positions 28 and 30. Here mediumto high-level resistant M28T/V and Q30H/R were mainly detected. Of note, 41% of individuals with NS5A RASs harbored NS3 Q80K, which is a higher prevalence compared with 35% in DAA-naïve patients. In GT1b, medium-level resistant Y93H was predominant (78%). Non-nucleoside NS5B RASs were infrequent within GT1a with slight increases of S556G and A553V observed, whereas the prevalence of low-level resistant S556G was relatively high in GT1b (69%) (Figure 4A and B) . The median sampling time was 3 months after EOT for both subtypes.
So far, we could investigate only 4 patients infected with GT4 and a failure to the 2D regimen. In NS3, all patients carried D168 variants and high-level resistant D168V was most frequent. The resistance pattern in NS5A was more diverse with increasing RASs at position L28 (75%), and here high-level resistant L28V was typically found ( Figure 4C ). For this limited number of patients, the sampling time points after EOT were varying.
Patterns of RASs and Retreatment Options
We identified typical patterns of RASs in individuals with a failure to a DAA-based treatment. In PI-experienced patients, RASs that were commonly selected after failure of a simeprevir-or a paritaprevir-based treatment were R155K in GT1a and D168E/V in GT1b. In GT4, different RASs at position Y56, Q80, and D168 appeared (Table 1) . Moreover, more than 3 months after EOT, NS3 RASs were detectable in only approximately one-half of PI-experienced patients with GT1b, whereas they were more frequent in GT1a (>80% including Q80 variants).
Regarding the NS5A inhibitor resistance profiles, we identified Q30H/R variants in GT1a as typical treatmentselected RASs, which were commonly detected after a daclatasvir, ledipasvir, and ombitasvir-based treatment. In contrast, the frequencies of Y93 variants were only moderate in GT1a and were variable according to the NS5A inhibitor used (rare after daclatasvir and ombitasvir, more frequent after ledipasvir). Altogether, the GT1a resistance pattern was diverse and included additional individual RASs for each regimen. In GT1b, Y93H was selected using each regimen. Interestingly, most patients had 1 NS5A RAS after treatment failure, except daclatasvir/sofosbuvirexperienced individuals with GT1b; here, 2 RASs were common, which can be attributed to the selection of L31M in combination with Y93H. Three RASs were not detected in GT1b-infected patients and were also rare in GT1a (Table 2) . Within GT4, NS5A RASs mainly appeared at position L28 and to a lesser extent at position Y93, but GT4 exhibits a diverse development of RASs according to the divergent subtypes.
Finally, we evaluated the theoretical treatment and retreatment options in accordance with broadly approved treatment regimens available for the different genotypes. In GT1-and GT4-infected patients, RASs within NS3 plus NS5A might impair a retreatment. For GT2 and 3, currently no PIs are available in many countries, and sofosbuvir/ribavirin is a suboptimal treatment for difficult-to-treat GT2-and all GT3-infected patients. Therefore, only NS5A RASs would represent a restriction for the retreatment of DAAexperienced patients. For all genotypes, S282T, which is rarely selected in patients with sofosbuvir failure, might limit a sofosbuvir-based retreatment. We determined that nearly all DAA-naïve individuals independent of the genotype could be RASs-free treated with at least 1 regimen.
For DAA-experienced patients, multiple options are available for GT1. As NS3 plus NS5A RASs are infrequent in = Figure 3 . Prevalence of NS5A RASs after daclatasvir/sofosbuvir or ledipasvir/sofosbuvir treatment failure compared with DAAnaïve patients in GT1a (A), GT1b (B), GT3 (C), and GT4 (D). The top of the figure shows the patient number included, the median time of the RAS analysis related to the EOT, and the range is indicated in parentheses. Patterns of RASs are highlighted using red frames with major increasing RASs labeled in red. According to References 12 and 54 to 56, resistance levels are specified at the bottom as well.
patients who received sofosbuvir plus 1 additional DAA, a retreatment according to the presence of RASs is possible for more than 80% of patients, as RASs are usually lacking for the alternative DAA target region. Major restrictions apply to 3D failures, in which multiple RASs in all DAA target regions enable a RASs-free retreatment only in 29% of patients. In GT3, Y93H is highly prevalent after daclatasvir/sofosbuvir failure, and therefore only 16% of patients could be retreated RASs-free, as alternative regimens not targeting NS5A are lacking so far. However, resistance development after ledipasvir/sofosbuvir is rare in GT3 because of the reduced antiviral activity, which enables a retreatment for 95% of patients. In GT4, RASs within NS3 plus NS5A are generally uncommon. Only in the 2D-treated individuals analyzed so far, NS3 plus NS5A RASs are frequent, precluding a RASs-free retreatment for all patients ( Figure 5 ).
Discussion
So far, data on the prevalence of HCV RASs were mainly available for treatment-naïve patients or for a small number of patients with DAA failure who participated in approval studies. In the present analysis, we investigated RASs in the real world in a large European resistance database comprising various patients with a DAA failure infected with HCV genotypes 1 to 4.
The development of RASs to sofosbuvir is rare. It seems, only S282T confers resistance in vitro and it was detected in a low number of patients after treatment failure only. [22] [23] [24] We identified S282T in a few patients after daclatasvir/ sofosbuvir or ledipasvir/sofosbuvir failure and it was rare in GT1 and GT3, but was more frequent in GT4. Moreover, L159F occurred in association with a sofosbuvir failure in GT1b and GT3 without conferring resistance in vitro, but the half maximal effective concentration was slightly increased together with S282T. 22, 25, 26 We observed slight increases of L159F in GT3, but it was frequently selected in combination with C316N in GT1b-infected patients who failed to sofosbuvir/ribavirin or other sofosbuvir-containing regimens as reported in another study. 27 Overall, the selection of sofosbuvir RASs is rare, and the importance of selected variants remains unclear. However, it is important to note that a retreatment with sofosbuvir seems to be associated with an increased likeliness for a treatment failure and selection of S282T. 4, 28 Similar to our study, after simeprevir/sofosbuvir failure, R155K and D168E were detected in GT1a, whereas in GT1b D168V was prominent and GT1b RASs vanished faster 
, not determined; not applicable, DAA regimen not approved for the respective genotype; no RASs, no RASs detected; no patients, DAA regimen is approved, but no samples were obtained. a Increase in prevalence after treatment failure <10%, but not detected in DAA-naïve patients. = Figure 4 . Frequencies of NS3, NS5A, and NS5B non-nucleoside RASs in patients without a response to a 3D treatment in GT1a (A) and GT1b (B), as well as after 2D treatment failure in patients with GT4 (C) in comparison with DAA-naïve individuals. The overall number of patients is specified at the top of the figure together with the median time of the RAS analysis in relation to the EOT, and the range is indicated in parentheses. Patterns of RASs are highlighted using red frames and increases of major RASs were marked in red. The resistance levels according to References 48 and 57 to 59, together with number of sequences analyzed, are stated at the bottom. compared with GT1a. 11, 29 Four months after EOT, we did not detect NS3 RASs anymore in more than one-half of GT1b-infected patients. The few GT4 simeprevir/sofosbuvir failure patients developed D168E, which was also identified in a pegylated-interferon-based study with simeprevir. 30 Most likely, the relatively short half-life of RASs selected by PIs explains high SVR rates in patients with PI-failure who received retreatment regimens including a PI plus sofosbuvir without an NS5A inhibitor. 31 Most patients with DAA failure in this study were treated with an NS5A inhibitor plus sofosbuvir and typical and diverse NS5A RASs patterns were observed depending on the NS5A inhibitor and the geno-/subtype. In GT1a, Q30H/R variants were selected after failure to both, daclatasvir or ledipasvir plus sofosbuvir. The selection of Y93 variants as major RASs was characteristic for ledipasvir/sofosbuvir, whereas only slight increases were observed after daclatasvir/sofosbuvir. Therefore, for a retreatment, the administration of second-generation NS5A inhibitors like velpatasvir and pibrentasvir 28, [32] [33] [34] [35] or the combination of sofosbuvir, grazoprevir, elbasvir, and ribavirin is feasible. 36 However, in daclatasvir/sofosbuvir failures, the lack of Y93H may enable effective retreatment options using ledipasvir or ombitasvir. Also, the combination of a PI like simeprevir plus sofosbuvir with or without ribavirin seems to be an effective retreatment option as naturally occurring simeprevir high-level resistant RASs are rare. [37] [38] [39] In GT1b, patterns of NS5A RASs were similar for ledipasvir and daclatasvir, and, compared with GT1a, Y93H was highly prevalent. As Y93H variants seem to persist in the long-term follow-up and confer also ombitasvir resistance, for GT1b retreatment, the inclusion of a PI is probably mandatory and a rescue treatment with simeprevir/sofosbuvir is also reasonable. Alternatively, regimens including a PI plus a second-generation NS5A-inhibitor could be used. 28, [32] [33] [34] [35] [36] Remarkably, we detected higher frequencies of NS5A RASs in GT1b compared with 1a (80%-90% vs 70%-80%) and this was even more pronounced in the ledipasvir/sofosbuvir approval studies (90% vs 70%). 7 Longer follow-up after virologic failure is required to determine potential differences in the half-life of NS5A RASs in GT1a vs 1b.
Failure to daclatasvir/sofosbuvir in GT3 was associated with a strong increase of Y93H, which was also shown in the approval study. 13 Remarkably, Y93H was not detected after ledipasvir/sofosbuvir, probably due to the reduced antiviral activity of ledipasvir in GT3. 40, 41 Second-generation NS5A inhibitors showed improved activities against GT3 isolates harboring Y93H and recently also GT3-sensitive PIs were approved. SVR rates after a rescue treatment with sofosbuvir plus a second-generation PI like voxilaprevir or pibrentasvir are not available. However, although SVR rates after retreatment with sofosbuvir/velpatasvir/voxilaprevir or initial treatment with glecaprevir/pibrentasvir were 95% and 97%, most failure patients were infected with GT3. 35, 42, 43 Thus, retreatment of GT3 failure patients most likely will remain a challenge, and the addition of ribavirin may increase treatment efficacy in difficult-to-treat patients. In GT3-infected patients with decompensated cirrhosis, SVR rates to velpatasvir/sofosbuvir were substantially lower compared with the group that additionally received ribavirin. 44 Moreover, a recent study suggested that the addition of ribavirin to retreatment regimens, like daclatasvir or velpatasvir plus sofosbuvir, could increase SVR rates. 45 Thus, the addition of ribavirin may be an option for rescue treatments in difficultto-treat GT3-infected patients as well as in DAA-naïve patients in countries in which second-generation DAA regimens will not be available in the near future.
In patients with GT4, we identified NS5A L28M and to a lesser extent Y93C/H/S as characteristic daclatasvir/sofosbuvir and ledipasvir/sofosbuvir failure RASs. Notably, the moderate frequency of Y93 variants enables a retreatment with velpatasvir/sofosbuvir, as these variants confer only low-level velpatasvir resistance.
The 3D regimen led to the selection of R155K in NS3 of GT1a and D168V in GT1b, which was detected frequently in combination with Y56H, enhancing the resistance level. This resistance profile is similar to that of simeprevir, but Y56H exclusively occurred after paritaprevir administration. Within GT1a NS5A, M28T/V and Q30H/R were mainly detected and M28 variants are characteristic for an ombitasvir treatment. 46 As M28 variants were not enriched after daclatasvir or ledipasvir, this may enable ombitasvir as a rescue option and may explain relatively high SVR rates in patients who received 3D as rescue treatment. 37 In GT1b, Y93H was the key RAS also for ombitasvir, and thus for all first-generation NS5A inhibitors. NS5B non-nucleoside RASs were rare in GT1a, but in GT1b, S556G was selected in combination with C316N. In the pivotal trials, the prevalence of GT1a RASs was comparable, but we detected higher frequencies of RASs in GT1b, which is explainable by the low number of GT1b-infected patients investigated in these studies. 46, 47 In GT4, typical RASs detected after 2D failure were D168V in NS3 and L28V in NS5A, whereas Y93 variants were infrequent. In the approval study, the 3 patients with a virologic failure developed similar RASs. 48, 49 As GT4 is rare in Europe, more patients with virologic failure have to be investigated to describe typical resistance patterns.
We considered (re)-treatment options with broadly approved DAAs based on RAS analyses. In DAA-naïve patients, moderate RAS frequencies and several treatment alternatives enable a RASs-free treatment for all GT. For DAA-experienced patients, the retreatment options according to the RASs-free approach are decreasing. Interestingly, 57% (GT1a), 93% (GT1b), and 100% (GT4) of patients with an NS5A inhibitor failure had no NS3 RAS, enabling a PI-based retreatment. Vice versa, 86% (GT1a) and 83% (GT1b) of PI-experienced individuals exhibited no NS5A RASs and might receive an NS5A inhibitor. Especially for 3D failures, alternatives are lacking, as RASs appear in multiple DAA targets and first-generation NS3 and NS5A inhibitor resistance profiles are overlapping. Another report also detected retreatment restrictions in patients with 3D failure and identified multiple RASs. 50 However, a retreatment using 3D plus sofosbuvir is efficient, as shown in a small study. 51 Other possible or recently approved retreatment options, like sofosbuvir/grazoprevir/elbasvir/ribavirin or sofosbuvir/velpatasvir/voxilaprevir, are highly effective in DAA-experienced patients and RASs had no apparent effect. 35, 36 As these second-generation and multiple targeting regimens are not available in many countries, recently reported experiences with rescue treatments in small groups of patients with DAA failure according to resistance profiles are of high importance. Data presented at recent international conferences showed high efficacies of this approach with SVR rates of approximately 90%. 37, 39 In the present study, geno-and subtype-specific resistance profiles of a large number of patients with DAA failure are described enabling quantitative and comparative comparisons. One limitation of this study is the noncontrolled analysis of samples from patients with DAA failure in a retrospective study. This could favor the analysis of, for example, difficult-to-treat patients with an urgent need of retreatment and may lead to a sample selection bias. The reported RAS frequencies therefore do not exactly represent the prevalence of RASs in European patients with DAA failure.
In summary, the identified typical treatment-selected resistance patterns for broadly currently used DAA regimens enable the selection of specific retreatment options based on the result of resistance analyses. However, resistance profiles for GT1b-and 3a-infected patients largely overlapped, which restricts individualized RASs-free retreatment options considerably.
Supplementary Material
Note: To access the supplementary material accompanying this article, visit the online version of Gastroenterology at www.gastrojournal.org, and at https://doi.org/10.1053/ j.gastro.2017.11.007.
* includes treatment-naive and PEG-IFN/RBV pre-treated patients ** includes patients treated with other DAAs from clinical studies ***published by Susser et al. J Hepatol. 2017 Overall n=4240 
